Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Transfer of Part of PMDA Functions to Osaka Proposed in Kansai Sogo Tokku Plan
August 1, 2011
- Astellas Licenses Transplant Viremia Prevention Vaccine from Vical
August 1, 2011
- Chugai Applies for Approval of Pulmozyme for Cystic Fibrosis
August 1, 2011
- Mochida, MTPC to Launch Lexapro on Aug. 22
August 1, 2011
- Sodium Phenylbutyrate from CMIC Designated as Orphan Drug
August 1, 2011
- Nihon Chouzai to Introduce Finger Vein Authentication at All Stores
August 1, 2011
- NPhA Withdraws Request to Refrain from Offering Points for Dispensing Services
August 1, 2011
- Ain Pharmaciez to Improve Its Services for Patients Using Smart Phones
August 1, 2011
- Rivaroxaban's Safety Found Non-inferior to Warfarin in Domestic PIII Study
August 1, 2011
- Pfizer Obtains Approval for Generics of 14 APIs
August 1, 2011
- US FDA Announces Draft Guidance for Simultaneous Development of Therapeutics and Companion Diagnostic Devices
August 1, 2011
- Daiichi Sankyo Espha to Deal with Both Long-listed Products, Generics
August 1, 2011
- Biosimilars Optimize Healthcare Costs: JSGM Seminar
August 1, 2011
- AZ, NCC Announce Comprehensive Agreement for Development of Anticancer Drugs
August 1, 2011
- Eisai Launches Halaven in Japan; Product to Be Detailed by All 1,400 MRs
August 1, 2011
- Volume-based Generics Market Share Up to 23.0% in FY 2010: JGA
August 1, 2011
- Shionogi Starts 4th PIII Study of the HIV Treatment S-349572
August 1, 2011
- Daiichi Sankyo Launches Lixiana for Prevention of VTE
August 1, 2011
- JGA Compiles Model Corporate Ethics Standards
August 1, 2011
- Takeda to Beef Up Its OTC Drugs Business in Asia
August 1, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…